How to Reconstitute PT-141 (Bremelanotide): Syringe Selection and Needle Gauge

Does PT-141 need to be reconstituted?

For the approved product, no. Vyleesi is bremelanotide 1.75 mg in a prefilled autoinjector pen that the patient self-administers [1]. There is no powder, no diluent and no separate syringe or needle to choose, so the usual questions about how much water, which barrel and which gauge do not apply.

What the Vyleesi label specifies

• Dose and route: 1.75 mg subcutaneously into the abdomen or thigh [1].
• Timing: as needed, at least 45 minutes before anticipated sexual activity [1].
• Limits: not more than one dose within 24 hours; more than 8 doses per month is not recommended [1].
• Delivery: self-administered via a prefilled autoinjector pen [1].
• Duration: the duration of efficacy after each dose is unknown, and the label says the optimal window for administration has not been fully characterized [1].

Compounded and research-use vials

Products sold as compounded or research-use 'PT-141' are not Vyleesi and are not FDA-approved drugs; compounded drugs are not reviewed by FDA for safety, effectiveness or quality before they are marketed [2][3]. Any diluent volume, concentration, insulin-syringe conversion or needle gauge for a self-mixed vial would not come from the Vyleesi label, which describes only the prefilled autoinjector [1].

What the label says to watch for

In the pooled phase 3 trials (Vyleesi n=627, placebo n=620): nausea 40.0% vs 1.3%, flushing 20.3% vs 0.3%, injection site reactions 13.2% vs 8.4%, headache 11.3% vs 1.9%, vomiting 4.8% vs 0.2% [1]. Pre-treating with oral ondansetron 30 minutes before the dose did not reduce nausea, and the label says it is not recommended [1]. Each dose transiently raises blood pressure and lowers heart rate; the label reports maximal increases of 6 mmHg systolic and 3 mmHg diastolic peaking 2 to 4 hours after the dose, usually back to baseline within 12 hours [1]. Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease [1].